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Abstract
Background/Aim. Atherosclerosis is still the leading cause
of death in Western world. Development of atherosclerotic
plaque involves accumulation of inflammatory cells, lipids,
smooth muscle cells and extracellular matrix proteins in the
intima of the vascular wall. Apolipoprotein E participates in
the transport of exogenous cholesterol, endogenously syn-
thesized lipids and triglycerides in the organism. Apolipo-
protein E gene has been identified as one of the candidate
genes for atherosclerosis. Previous studies in different
populations have clearly implicated apolipoprotein E ge-
netic variation (? polymorphisms) as a major modulator of
low density lipoprotein cholesterol levels. Data considering
apolipoprotein E polymorphisms in relation to carotid ath-
erosclerosis gave results that are not in full compliance. The
aim of present study was to investigate the apolipoprotein E
polymorphisms in association with carotid plaque presence,
apolipoprotein E and lipid serum levels in patients with ca-
rotid atherosclerosis from Serbia. Methods. The study
group enrolled 495 participants: 285 controls and 210 con-
secutive patients with carotid atherosclerosis who under-
went carotid endarterectomy. Genotyping of apolipoprotein
E polymorphisms were done using polymerase chain reac-
tion and restriction fragment length polymorphism meth-
ods. Results. Patients had significantly decreased frequency
of the ?2 allele compared to controls. Patients who carry at
least one ?2 allele had a significantly higher level of serum
apolipoprotein E and significantly lower low density lipo-
protein cholesterol levels compared to those who do not
carry this allele. Conclusion. Our results suggest protective
effect of apolipoprotein E ?2 allele on susceptibility for ca-
rotid plaque presence as well as low density lipoprotein
cholesterol lowering effect in Serbian patients with carotid
atherosclerosis. Further research of multiple gene and envi-
ronmental factors that contribute to the appearance and the
progression of atherosclerosis should be continued with re-
spect to different populations.
Key words:
genetic predisposition to disease; carotid artery
disease; polymorphism, genetic; apolipoproteins e.
Apstrakt
Uvod/Cilj. Ateroskleroza je vode?i uzro?nik smrtnosti u
zapadnom svetu. Proces formiranja aterosklerotskog plaka
podrazumeva akumulaciju ?elija inflamatornog odgovora,
lipida, glatkih miši?nih ?elija i proteina van?elijskog matriksa
u intimi zida krvnog suda. Apolipoprotein E u?estvuje u
transportu egzogenog holesterola, endogeno sintetisanih li-
pida i triglicerida u organizmu. Gen koji kodira apolipopro-
tein E smatra se jednim od gena kandidata u izu?avanju ate-
roskleroze. Rezultati prethodnih studija, ura?enih na razli?i-
tim populacijama, jasno ukazuju da su varijacije u genu za
apolipoprotein E glavni modulatori nivoa lipoproteina male
gustine u serumu. Do sada objavljeni rezultati koji se ti?u
povezanosti polimorfizama u genu za apolipoprotein E sa
aterosklerozom karotidnih arterija su kontradiktorni. Zato je
cilj ove studije bio da se ispita povezanost polimorfizama u
genu za apolipoprotein E sa rizikom od nastanka ateroskle-
rotskog plaka u karotidnim arterijama kao i sa nivoom pro-
teina apolipoprotein E i lipida u serumu bolesnika sa ateros-
klerozom karotidnih arterija iz Srbije. Metode. Ovom stu-
dijom bilo je obuhva?eno ukupno 495 ispitanika: 285 zdra-
vih ispitanika u kontrolnoj grupi i 210 bolesnika sa ateros-
klerozom karotidnih arterija koji su bili upu?eni na endarte-
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rektomiju. Genotipizacija polimorfizama u genu za apolipo-
protein E je ura?ena metodama lan?ane reakcije polimeraze
i analizom fragmenata dobijenih digestijom sa restrikcionim
enzimima. Rezultati. Bolesnici su imali statisti?ki zna?ajno
manju frekvenciju alela ?2 u odnosu na kontrolnu grupu. Is-
pitanici koji su bili nosioci genotipa sa bar jednom kopijom
alela ?2 imali su statisti?ki zna?ajno viši nivo proteina apoli-
poprotein E i statisti?ki zna?ajno niži nivo lipoproteina male
gustine u serumu u odnosu na bolesnike koji su bili nosioci
genotipova bez prisustva alela ?2. Zaklju?ak. Rezultati ove
studije ukazuju na zaštitni efekat alela ?2 od nastanka atero-
sklerotskog plaka u karotidnim arterijama, kao i povezanost
sa nižim nivoom lipoproteina male gustine u serumu boles-
nika sa njihovom aterosklerozom. Neophodna su dalja is-
traživanja gena i faktora rizika iz spoljašnje sredine uklju?e-
nih u nastanak ateroskleroze u razli?itim populacijama.
Klju?ne re?i:
bolest, genetska, predispozicija; a.carotis, bolesti;
polimorfizam, geneti?ki; apolipoproteini e.
Introduction
As a multifactorial vascular disease, atherosclerosis is
one of the most frequently occurring illnesses of the modern
world. According to the theory given by Ross and Glomset 1,
which is still among the most common, atherosclerosis is
initiated by a blood vessel injury accompanied by inflam-
matory processes. Plaque, an accumulation of cells with dif-
ferent content (including lipids), forming on the inside of
blood vessels in the area of injury can lead to a large lumen
narrowing (stenosis) of the vessel 2. The consequences of
atherosclerotic lesions rupture may be heart attack or stroke,
which eventually could lead to death.
Taking into account the causes and consequences asso-
ciated with the formation of atherosclerotic plaques, effective
prevention of this disease including genetic data and epide-
miological studies could provide the only permanent solution
to combat this disease. Many genes can be considered as
candidates whose polymorphisms in interaction with certain
risk factors such as: dyslipidemia, hypertension, obesity,
stress, smoking, diabetes and physical inactivity, can lead to
the development and/or progression of atherosclerosis 3–5.
Apolipoprotein E gene (APOE) has been identified as
one of the candidate genes for atherosclerosis. Apolipopro-
tein E (apoE) is apolipoprotein which plays a major role in
regulating the metabolism of chylomicrons, very low density
lipoproteins (VLDL), and high density lipoproteins (HDL)
via the apoE receptor and by the low density lipoprotein
(LDL) receptors 6. It is responsible, in part, for uptake of
dietary cholesterol in the form of chylomicron remnants,
clearence of VLDL remnants, and removal of the excess
cholesterol from peripheral tissues through hepatic clearance
of HDL containing apoE 6. Thus, ApoE participates in the
transport of exogenous cholesterol, endogenously synthe-
sized lipids and triglycerides (TG) in the organism 7. This
protein has two domains: the C-terminal, which is associated
with lipoprotein particles and the N-terminal, which binds to
the lipoprotein receptor 8, 9.
Polymorphisms in the APOE analyzed in this study are
located in a region that encodes the N-terminal domain of
apoE protein. Depending on whether the Arg or Cys are pres-
ent in two polymorphic positions (codons 112 and 158), the
possible alleles are: ?2 (112 Cys, 158 Cys), ?3 (112 Cys, 158
Arg) and ?4 (112 Arg, 158 Arg) 10. Previous studies in differ-
ent populations have clearly implicated APOE genetic varia-
tion as a major modulator of LDL cholesterol levels 11–13. The
?2 allele carriers have decreased, whereas ?4 carriers have in-
creased the level of cholesterol compared to the ?3 allele carri-
ers 14. A meta analysis by Dallongeville et al. 15 indicated that
subjects with the ?2 and ?4 alleles had higher triglyceride lev-
els than subjects with the ?3 allele. Blood lipid level has been
recognized as risk factor for carotid artery plaque formation,
so variation at APOE locus could be a major determinant of
atherosclerosis risk in the general population.
Previously published studies, which investigated APOE
polymorphisms in relation to carotid atherosclerosis, gave re-
sults that are not in full compliance. The ?2 allele was asso-
ciated with a reduced risk for carotid plaque presence, com-
pared with the presence of allele ?3 16. In other study the
same was suggested for the carriers of E4 allele 17.
Since the formation of a plaque via lipid accumulation
on the inside of the vessel is an important factor for the ini-
tiation of atherosclerosis, and there is no clear conclusion
about which of the APOE alleles or genotypes are associated
with the carotid plaque (CP) presence the present study ex-
amined the APOE polymorphisms in association with CP
presence, apoE and lipid serum levels in carotid atheroscle-
rosis (CA) patients from Serbia who underwent carotid end-
arterectomy.
Methods
Subjects
The study group enrolled 495 participants: 285 controls
and 210 consecutive patients with CA who underwent ca-
rotid endarterectomy. All the participants were Caucasians of
European descendent from Serbia. From all of them medical
history was collected including smoking and drinking habits,
presence of diabetes, peripheral arterial occlusive disease,
coronary artery disease and drug treatment. Exclusion crite-
ria for all patients were carotid kinking, carotid aneurism,
history of previous carotid endarterectomy (possible resteno-
sis), tumors, autoimmune disease, chronic inflammatory dis-
eases or renal failure. The patients already diagnosed with
diabetes mellitus, having a fasting glucose ? 7.0 mmol/L, or
taking insulin or hypoglycemic drugs were classified as
having diabetes mellitus. Those with previous myocardial in-
fraction or stable angina pectoris evaluated by selective co-
ronography that confirmed coronary artery disease were
classified as having coronary heart disease. Peripheral artery
disease was diagnosed in those with an ankle–brachial index
< 0.90. Hypertension was defined as systolic blood pressure
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? 140 mmHg, a diastolic blood pressure ? 90 mmHg, or cur-
rent treatment with antihypertensive drugs 18. From the indi-
viduals undergoing annual medical check-up at Occupational
Medical Center, Belgrade, Serbia, who underwent clinical
and ECG examination, 285 that were without evidence of
CA, cerebrovascular or cardiovascular disease, any chronic
inflammatory disease, renal failure or diabetes mellitus were
recruited as controls 19.
A total of 210 patients were recruited from individuals
consecutively admitted for carotid endarterectomy to the
Clinic for Vascular and Endovascular Surgery, Clinical Center
of Serbia, Belgrade, Serbia, during 2008 with evidence of ca-
rotid plaque in the internal carotid artery (ICA) or common ca-
rotid artery (CCA). Ultrasound assessment of the bilateral ca-
rotid arteries was performed as previously described 18.
Atherosclerotic plaques were defined as focal widening
relative to adjacent segments as evidenced by protrusion into
the lumen and/or localized roughness with increased echo-
genicity. For ultrasound carotid measurements, intraclass
correlation coefficients for inter-rater and intra-rater reliabil-
ity were 0.916 and 0.968, respectively. Carotid atherosclero-
sis was defined as the presence of atherosclerotic plaques in
internal or common carotid artery 18.
All biochemical analyses were performed at the hospital
laboratory by standard procedure.
The study was approved by Ethic Committee of the
participating medical center with written informed consent
given by each participant in this study.
Genetic analysis
Genomic DNA was isolated from the whole blood
samples collected with ethylenediamine tetraacetic acid
(EDTA) by standardized BloodPrep® DNA Chemistry iso-
lation kit (Applied Biosystems, Forester City, CA) on the
ABI PRISM™ 6100 Nucleic Acid PrepStation (Applied
Biosystems, Forester City, CA). Genotyping of APOE
polymorphisms was done by polymerase chain reaction
(PCR) using the following primers: forward 5'-
TAAGCTTGGCACGGCTGTCCAAGGA-3' and reverse 5'-
ACAGAATTCGCCCCGGCCT GGTACAC-3', designed
according to the previously described protocol 20. PCR mix-
ture component concentrations were as follows: 1X PCR
buffer (10X), 1.5 mM MgCl2, 1% DMSO, 0.2 mM dNTP, 0.45
mM  of each primer, 0.25 U/?l Taq polymerase. Temperature
conditions of the PCR reaction were as follows: 95 °C 7 min.,
and 33 cycles (95 °C 40s, 65 °C 30s, 72 °C 60s) without a fi-
nal extension step. After PCR, the synthesized fragment was
244 bp in length. Restriction analysis of synthesized DNA
fragments (RFLP) was carried out by a Hin6I-mediated di-
gestion of amplified PCR fragments. The lengths of the
fragments obtained by digestion with the enzyme Hin6I are
as follows: E2: 36bp, 16bp, 91bp, 18bp, 83bp; E3: 36bp,
16bp, 91bp, 18bp, 48bp, 35bp; E4: 36bp, 16bp, 19bp, 72bp,
18bp, 48bp, 35bp. The digestion products were loaded on an
8% polyacrilamide gel for genotyping and run for 2 h in
electric field of 12 V/cm. Gels were stained with silver ni-
trate and visualized using a GDS8000 gel documentation
system (Ultra Violet Products Inc, Upland, USA).
Statistical analysis
The allelic frequencies and genotype distribution were
estimated by gene counting method. Differences in allele
frequencies and genotype distribution between the cases and
controls as well as deviation from Hardy-Weinberg equilib-
rium were estimated by ?2. Normal distribution of continuous
variables was tested by Kolmogorov-Smirnov test with Lil-
lieform's correction. The influence of genotype on the vari-
ability of biochemical parameters was analyzed using
ANOVA and appropriate post-hoc test or Kruskal Waliss
ANOVA as a nonparametric test. The results are presented as
mean ± standard deviation (SD). Statistical analysis was per-
formed using Statistica Version 8, software package
(StatSoft Inc, 2008). In all tests, differences with two-tailed
alpha–probability p < 0.05 were considered significant.
Results
This study examined the association of APOE poly-
morphisms with the carotid atherosclerotic plaque presence.
The study included 285 subjects in the control (healthy)
population and 210 patients with CA. None of the genders
was significantly prevalent in any of the groups (49.64% of
women and 50.36% of men in the control population and
42.58% women and 57.42% men in the atherosclerotic
population, p > 0.05). However, the group of patients was
significantly older than the control population (age of the
control population was 51.50 ± 9.30 years and of the pa-
tients’ group it was 60.02 ± 10.08 years, p < 0.01). The rela-
tive frequencies of APOE genotypes did not deviate signifi-
cantly from Hardy-Weinberg equilibrium and differences in
their distribution between the studied groups were not statis-
tically significant (Table 1).
Table 1
Relative frequencies of apolipoprotein E (APOE) genotypes in the controls
 and the group of patients with carotid atherosclerosis
Control group Patient groupGenotype  n (%)  n (%) p
E2/2 6 (2.11) 3 (1.43)
E2/3 44 (15.44) 17 (8.10)
E2/4 5 (1.75) 0 (0.00)
E3/3 188 (65.96) 156 (74.29) NS
E3/4 39 (13.68) 32 (15.24)
E4/4 3 (1.05) 2 (0.95)
Total 285 (100) 210 (100)
p – Pearson ?2 test; NS – not statistically significant.
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Allele frequency distribution was significantly different
between the patients and the controls (Table 2). The ?2 allele
had significantly decreased frequency in the patient group
compared to the controls (?2 = 11.5, df = 1, p < 0.01).
Table 2
Relative frequencies of apolipoprotein (APOE) alleles in the
controls and the patients with carotid atherosclerosis
Alelle Controls (%) Patients (%) p*
?2 0.11 0.05
?3 0.80 0.86
?4 0.09 0.09
 < 0.05
*Pearson ?2 test.
We also measured concentrations of apoE in the serum
of patients with carotid atherosclerosis. Concentrations of
apoE, represented as mean ± SD, were not significantly dif-
ferent according to the APOE genotypes (Table 3).
Table 3
Mean serum concentration of apolipoprotein E (apoE) with
the reference to apolipoprotein E (APOE) genotypes
ApoE (mg/L)Genotype n mean ± SD
E2/2 1 103.20 ± 0.00
E2/3 11 69.14 ± 36.37
E2/4 0 0.00 ± 0.00
E3/3 76 46.98 ± 11.54
E3/4 15 42.75 ± 10.75
E4/4 2 35.30 ± 15.13
Total 105 49.01 ± 18.01
Nevertheless, when we grouped APOE genotypes in
those containing ?2 allele (E2/E2 + E2/E3), ?4 allele (E3/E4
+ E4/E4) and homozygotes for the ?3 allele (E3/E3) (not in-
cluding the genotype E2/4), Kruskal-Wallis ANOVA test
showed a statistically significant difference (p < 0.01) in se-
rum apoE levels among these groups of genotypes. The pa-
tients who carried at least one ?2 allele (E2/E2 + E2/E3) had
a significantly higher level of serum apoE compared to those
with E3/3 and E3/E4 + E4/4 genotypes (Table 4).
Table 4
Mean serum concentrations of apolipoprotein E (apoE) in
the serum of patients by the grouped genotype
ApoE (mg/L)Genotype n mean ± SD p*
E2/2 + E2/3 12 71.98 ± 36.05
E3/3 76 46.98 ± 11.54
E3/E4 + E4/4 17 41.88 ± 11.03
Total 105 49.01 ± 18.01
< 0.01
*Kruskal-Wallis ANOVA.
We also examined values of lipid parameters measured
in the serum of patients with atherosclerosis according to the
grouped apoE genotypes, excluding E2/E4 genotype (Table
5). ANOVA LSD post-hoc test revealed that the carriers of at
least one ?2 allele had significantly lower LDL cholesterol
levels compared to those who did not carry this allele. The
concentrations of HDL cholesterol and triglyceride levels
were not significantly different (p > 0.05) according to the
grouped genotypes.
Discussion
This study investigated a possible association of APOE
polymorphisms with the occurrence of carotid plaque as well
as with apoE and lipid serum values in Serbian patients with
CA. There were no statistically significant differences in the
frequencies of APOE genotypes between the two groups, but
there was a statistically significant decrease in the frequency
of allele ?2 in the group of patients compared to the controls.
This result indicates the protective effect of the ?2 allele for
carotid plaque presence and is consistent with previous
studies 16, 21. Some studies have shown that the ?2 allele con-
tributes to the reduced risk of atherosclerosis occurrence only
if subjects are of normal weight and younger than 80 22. The
presence of ?2 allele has also been shown to lead to the
smallest intima media thickness 16, 23.
This study, however did not demonstrate compliance
with some of the results from previous studies in respect to
the ?4 allele. It was characterized as atherogenic in French
and Thai population 21, 24, but not in the Caucasians from The
Rotterdam study 16. Concordantly with our results, they did
not find any significant association of the ?4 allele with ca-
rotid plaques presence in a large sample of more than 4,000
Caucasians 16. The majority of studies showed contradictory
results regarding the impact of different APOE alleles on the
development of atherosclerosis 16, 17, 21, 23–25. Potential reasons
for the conflicting results in these studies may be: a non-
representative sample, analysis of different age groups of
persons and/or different stages of the illness, different envi-
ronmental conditions, and different ethnic origin. Frequency
of the ?4 allele in the Serbian population was in concordance
with the frequency obtained from Italian population and the
study group of Caucasians investigated in The Rotterdam
study 14, 16.
The obtained values of serum apoE concentrations indi-
cate a declining trend in the direction: E2/2 > E2/3 > E3/3 >
E3/4 > E4/4. After grouping of the genotypes, it was found
Table 5
Mean serum values of lipid parameters according to the grouped
apolipoprotein E (APOE) genotypes
Genotype n HDLC (mmol/L)mean ± SD
LDLC (mmol/L)
mean ± SD
TG (mmol/L)
mean ± SD
E2/E2 + E2/E3 16 1.09 ± 0.37 3.09 ± 1.17* 2.08 ± 0.92
E3/E3 126 1.17 ± 0.35 3.79 ± 1.06 1.80 ± 0.78
E3/E4 + E4/E4 26 1.20 ± 0.32 3.88 ± 1.07 1.58 ± 0.68
Total 168 1.17 ± 0.35 3.74 ± 1.09 1.79 ± 0.78
*p < 0.05; [ANOVA, Fisher’s Least Significant Difference (LSD)] post hoc test;
HDLC- HDL cholesterol; LDLC- LDL cholesterol; TG – triglycerides.
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that carriers of at least one ?2 allele had significantly in-
creased, and the carriers of at least one ?4 allele significantly
decreased apoE levels in serum, compared to the carriers of
genotype E3/3. These results are consistent with previous
studies 16, 26. According to Weisgraber et al. 8, ApoE3 and
ApoE4 isoforms have normal receptor-binding activity be-
cause arginine is at the position 158 in the protein, unlike
ApoE2 isoforms, which at this position contains cysteine and
binds to the receptor with reduced efficiency.
Among patients with CA, the carriers of at least one ?2
allele showed a significant reduction in LDL cholesterol lev-
els compared to the carriers of any other genotype, while no
significant differences in the level of HDL cholesterol was
noted between genotypes. Previously published results for
the random population from Serbia 27 have shown the same
pattern. The results we got for the LDL cholesterol levels
correspond to previous studies 16, 28, 29. From the obtained re-
sults it can be concluded that the ?2 allele has atheroprotec-
tive function, but the exact mechanism of ApoE2 and ApoE4
isoforms’ influences on LDL cholesterol remains unknown.
This study found no association of APOE genotypes
and HDL cholesterol levels, which is consistent with the re-
sults of some previous studies 30 but differs from others 31.
HDL participates in reverse cholesterol transport from pe-
ripheral tissues to the liver, thereby performing the athero-
protective role. Also, our study showed no statistically sig-
nificant association of APOE genotype with serum triglyc-
eride levels. Analyzing the results from numerous studies
there is no evidence of a consistent relationship between the
APOE genotypes and triglyceride or HDL levels 32. Thus, we
can assume that the effect APOE genotypes could have on
variability of HDL or triglycerides is rather small or popula-
tion specific.
Conclusion
This study suggests a protective effect of APO ?2 allele
on carotid plaque presence as well as LDL cholesterol low-
ering effect. A considerable number of contradictory results
regarding the exact role of APOE polymorphisms in the de-
velopment and progression of atherosclerosis are a conse-
quence of the very nature of atherosclerosis as a disease. The
development of atherosclerosis depends on a large number of
both genetic (other apolipoprotein isoforms, polymorphisms
in genes for proteins involved in inflammatory processes),
and environmental factors (lifestyle, therapy, diet). In order
to get the most reliable results on the genetic causes of ath-
erosclerosis, it is certainly necessary to do analysis of multi-
ple genes in a representative sample of healthy and diseased
individuals and to estimate the risk accurately by adjusting
for confounding factors. Also, it is possible that ApoE per-
forms a dual function in apoE-related transport of lipids in
the body and so the balance between processes that it per-
forms determines its atherogenic or atheroprotective role in
atherosclerosis. Further research of multiple gene and envi-
ronmental factors that contribute to the appearance and the
progression of atherosclerosis should be continued with re-
spect to different populations.
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